111 related articles for article (PubMed ID: 8817248)
21. Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus.
Niskanen L; Laakso M
Metabolism; 1993 Dec; 42(12):1541-5. PubMed ID: 8246767
[TBL] [Abstract][Full Text] [Related]
22. Low-dose iloprost infusion improves insulin action in aged healthy subjects and NIDDM patients.
Paolisso G; Di Maro G; D'Amore A; Passariello N; Gambardella A; Varricchio M; D'Onofrio F
Diabetes Care; 1995 Feb; 18(2):200-5. PubMed ID: 7537193
[TBL] [Abstract][Full Text] [Related]
23. Effects of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans.
Saunders JP; Donner TW; Sadler JH; Levin GV; Makris NG
Regul Toxicol Pharmacol; 1999 Apr; 29(2 Pt 2):S57-65. PubMed ID: 10341162
[TBL] [Abstract][Full Text] [Related]
24. Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients.
Emanuel AL; de Clercq NC; Koopen AM; van Poelgeest E; Serlie MJM; van Raalte DH; Kramer MHH; Nieuwdorp M; Eringa EC; Serné EH
Diabetes Obes Metab; 2018 Nov; 20(11):2523-2531. PubMed ID: 29885045
[TBL] [Abstract][Full Text] [Related]
25. Improvement in glucose tolerance after 1 wk of exercise in patients with mild NIDDM.
Rogers MA; Yamamoto C; King DS; Hagberg JM; Ehsani AA; Holloszy JO
Diabetes Care; 1988 Sep; 11(8):613-8. PubMed ID: 3065001
[TBL] [Abstract][Full Text] [Related]
26. Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate.
Galgani JE; Heilbronn LK; Azuma K; Kelley DE; Albu JB; Pi-Sunyer X; Smith SR; Ravussin E;
Diabetes; 2008 Apr; 57(4):841-5. PubMed ID: 18285553
[TBL] [Abstract][Full Text] [Related]
27. Presentation of a new method for specific measurement of in vivo insulin-stimulated glucose disposal in humans: comparison of this approach with the insulin clamp and minimal model techniques.
Donner CC; Fraze E; Chen YD; Hollenbeck CB; Foley JE; Reaven GM
J Clin Endocrinol Metab; 1985 Apr; 60(4):723-6. PubMed ID: 3882738
[TBL] [Abstract][Full Text] [Related]
28. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid.
Kamenova P
Hormones (Athens); 2006; 5(4):251-8. PubMed ID: 17178700
[TBL] [Abstract][Full Text] [Related]
29. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes.
Evans JL; Goldfine ID
Diabetes Technol Ther; 2000; 2(3):401-13. PubMed ID: 11467343
[TBL] [Abstract][Full Text] [Related]
30. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
Maheux P; Ducros F; Bourque J; Garon J; Chiasson JL
Int J Obes Relat Metab Disord; 1997 Feb; 21(2):97-102. PubMed ID: 9043962
[TBL] [Abstract][Full Text] [Related]
31. Insulin action and fibrinolysis influenced by vitamin E in obese Type 2 diabetes mellitus.
Skrha J; Sindelka G; Kvasnicka J; Hilgertová J
Diabetes Res Clin Pract; 1999 Apr; 44(1):27-33. PubMed ID: 10414937
[TBL] [Abstract][Full Text] [Related]
32. Insulin action in black Americans with NIDDM.
Banerji MA; Lebovitz HE
Diabetes Care; 1992 Oct; 15(10):1295-302. PubMed ID: 1425092
[TBL] [Abstract][Full Text] [Related]
33. Quantitation of insulin-stimulated glucose disposal in patients with non-insulin-dependent diabetes mellitus.
Donner CC; Fraze E; Chen YD; Reaven GM
Diabetes; 1985 Sep; 34(9):831-5. PubMed ID: 2863188
[TBL] [Abstract][Full Text] [Related]
34. Metabolic effects of thioctic acid in rodent models of insulin resistance and diabetes.
Black K; Qu X; Seale JP; Donnelly R
Clin Exp Pharmacol Physiol; 1998 Sep; 25(9):712-4. PubMed ID: 9750961
[TBL] [Abstract][Full Text] [Related]
35. Peripheral, rather than hepatic, insulin resistance and atherogenic lipoprotein phenotype predict cardiovascular complications in NIDDM.
Nosadini R; Manzato E; Solini A; Fioretto P; Brocco E; Zambon S; Morocutti A; Sambataro M; Velussi M; Cipollina MR
Eur J Clin Invest; 1994 Apr; 24(4):258-66. PubMed ID: 8050454
[TBL] [Abstract][Full Text] [Related]
36. Effect of misoprostol (PGE1) on glucose metabolism in type-2-diabetic and control subjects.
Lee NA; Matsuda M; Bressler P; Pratipanawatr T; Glass L; Mandarino LJ; DeFronzo RA
Diabetes Obes Metab; 2002 May; 4(3):195-200. PubMed ID: 12047398
[TBL] [Abstract][Full Text] [Related]
37. Controversies surrounding the clinical potential of cinnamon for the management of diabetes.
Rafehi H; Ververis K; Karagiannis TC
Diabetes Obes Metab; 2012 Jun; 14(6):493-9. PubMed ID: 22093965
[TBL] [Abstract][Full Text] [Related]
38. Insulin-stimulated glucose disposal increases with time in patients with non-insulin-dependent diabetes mellitus.
Liu G; Chen YD; Hollenbeck CB; Lardinois CK; Reaven GM
Diabetes; 1984 Jul; 33(7):643-7. PubMed ID: 6376220
[TBL] [Abstract][Full Text] [Related]
39. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration.
Facchini F; Chen YD; Hollenbeck CB; Reaven GM
JAMA; 1991 Dec; 266(21):3008-11. PubMed ID: 1820474
[TBL] [Abstract][Full Text] [Related]
40. The hot but not the cold minimal model allows precise assessment of insulin sensitivity in NIDDM subjects.
Avogaro A; Vicini P; Valerio A; Caumo A; Cobelli C
Am J Physiol; 1996 Mar; 270(3 Pt 1):E532-40. PubMed ID: 8638702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
